Is A Renaissance In Surging Biotechs Underway?

By Gene Marciel

Not too long ago, investing in biotechnology was perceived as plain gambling. The rewards could be high, to be sure, but so were the risks in playing the arcane biotech stocks.

That was because a biotech company’s success depended on the development of important drugs that could achieve government regulatory approval. Not only was it extremely difficult to develop effective treatments for serious ailments, but it was equally as difficult to persuade the Food And Drug Administration to approve their use.

But in recent years, the biotech industry has become an attractively rewarding sector for investors as the FDA bolstered its system to accelerate its approval process, particularly in the case of life-saving drugs. That was in large part due to the advance and fast progress by the biotech companies in producing new and novel treatments for a variety of diseases.